Generics

Dr. Reddy's is rolling out generic chlorthalidone tablets, which had a market value of about $122 million.

The FDA has given the green light to Celltrion for Truxima, the first biosimilar to Rituxan for non-Hodgkin's lymphoma.

Perrigo is offering generic diclofenac sodium gel, which had a market value of about $31 million.

Akorn has received the FDA's approval for diclofenac sodium topical gel, which had a market value of about $357 million.

Teva is rolling out limited doses of its generic EpiPen for patients with life threatening allergic emergencies.

Perrigo has received the FDA's tentative nod for generic Ultravate lotion, which had a market value of about $17 million.

Lupin received FDA approval for generic Anafranil capsules, and generic potassium chloride oral solution, which had a market value of about $109.6 million, and $105 million, respectively.

Following a court ruling in its favor, Dr. Reddy's will resume launch activities for its generic Suboxone sublingual film, which provides a treatment for opioid addiction.